Cancer Stem Cell News Volume 11.01 | Jan 12 2022

2022-01-12 | CSCN 11.01

Cancer Stem Cell News by STEMCELL Technologies
Vol. 11.01 – 12 January, 2022

Glioblastoma Stem Cells Reprogram Chromatin In Vivo to Generate Selective Therapeutic Dependencies on DPY30 and Phosphodiesterases

Scientists identified Dyp-30 histone methyltransferase complex regulatory subunit (DPY30), a regulator of histone H3 lysine 4 trimethylation, as a driver of glioblastoma growth in vivo but not in vitro.
[Science Translational Medicine]

Full Article

New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.
PUBLICATIONSRanked by the impact factor of the journal

O-linked α2,3 Sialylation Defines Stem Cell Populations in Breast Cancer

Researchers identified a lectin, SLBR-N, which bound to O-linked α2,3 sialic acids, that was able to enrich for CSCs in vitro and in vivo. This O-glycan was expressed on CD44 and promoted its interaction with hyaluronic acid, facilitating CD44 signaling and CSC properties.
[Science Advances]

Full Article

Quiescent Human Glioblastoma Cancer Stem Cells Drive Tumor Initiation, Expansion, and Recurrence Following Chemotherapy

A derived quiescent CSC-specific gene expression signature was enriched in pre-formed patient glioblastoma xenograft single-cell clusters that lacked proliferative gene expression.
[Developmental Cell]

AbstractGraphical Abstract

Tfap2b Specifies an Embryonic Melanocyte Stem Cell That Retains Adult Multifate Potential

The authors found that Tfap2b and a select set of target genes specified an melanocyte stem cell population at the dorsal root ganglia in zebrafish.
[Cell Reports]

Full ArticleGraphical Abstract

Targeting HIF-1α/NOTCH1 Pathway Eliminates CD44+ Cancer Stem-Like Cell Phenotypes, Malignancy, and Resistance to Therapy in Head and Neck Squamous Cell Carcinoma

Scientists compared the gene expression between CD44+ and CD44− HNSCC cells and assessed the correlation of CD44 and hypoxia-inducible factor 1α expression with mouse features and outcomes of patients with head and neck squamous cell carcinomas.


Induction of Cancer Cell Stemness in Glioma through Glycolysis and the Long Noncoding RNA HULC-Activated FOXM1/AGR2/HIF-1α Axis

Brain tissues were clinically collected from 50 patients with glioblastoma and 35 patients with acute craniocerebral injury, followed by immunohistochemical detection of the expression patterns of Forkhead box M1 (FOXM1), anterior gradient 2 (AGR2), and hypoxia-inducible factor-1α (HIF-1α).

[Laboratory Investigation]


The Efficacy of PI3Kγ and EGFR Inhibitors on the Suppression of the Characteristics of Cancer Stem Cells

Investigators established a model of CSCs that was originally developed from mouse induced pluripotent stem cells (miPSCs) by proposing miPSCs to the conditioned medium of cancer derived cells, which was a mimic of carcinoma microenvironment.
[Scientific Reports]

Full Article

New Repurposed Rolapitant in Nanovesicular Systems for Lung Cancer Treatment: Development, In Vitro Assessment and In Vivo Biodistribution Study

Scientists evaluated the in vitro drug release, in vitro cytotoxicity on A549 lung cancer cells, nebulization performance using next generation impactor, and the in vivo biodistribution behavior of lipid nanovesicles encapsulating rolapitant.
[European Journal of Pharmaceutical Sciences]

Full ArticleGraphical Abstract

Knockdown of Zinc Finger Protein 267 Suppresses Diffuse Large B-Cell Lymphoma Progression, Metastasis, and Cancer Stem Cell Properties

Researchers found that zinc finger protein 267 was significantly upregulated in diffuse large B-cell lymphoma and predicted a poor survival outcome based on the bioinformatics analysis.

Full Article

Molecular Changes in Adipocyte-Derived Stem Cells during Their Interplay with Cervical Cancer Cells

Investigators analyzed the expression profile of adipose tissue-derived stem cells co-cultured with cervical cancer cells through massive RNA sequencing followed by evaluation of various functional alterations resulting from the modified transcriptome.
[Blood Cancer Discovery]


Subscribe to Science News for free weekly science newsletters.

Harnessing Cytokines and Chemokines for Cancer Therapy

The authors discuss the lessons learnt from the initial trials of single-agent cytokine-based therapies and subsequent efforts to better exploit such agents for the treatment of solid tumors.
[Nature Reviews Clinical Oncology]


The Role of Mesenchymal Stem Cells in the Occurrence, Development, and Therapy of Hepatocellular Carcinoma

Investigators analyzed the role of mesenchymal stem cells (MSCs) in the tumor microenvironment and summarized the relationship between MSCs and liver cancer stem cells.
[Cancer Medicine]

Full Article


Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Lixte Biotechnology Holdings, Inc. reported that its recent collaboration with the Netherlands Cancer Institute, Amsterdam, and Stichting Oncode Institute, Utrecht, has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds.
[Lixte Biotechnology Holdings, Inc.]

Press Release


Keystone Symposia – Cancer Neoantigens, Vaccines and Viruses

February 6 – 10, 2022
Banff, Alberta, Canada

> See All Events


Postdoctoral Research Associate – Drug Responses in Glioblastoma

Queen Mary University of London – London, United Kingdom

Postdoctoral Research Associate – Tumor Stem Cells

Queen Mary University of London – London, United Kingdom

Scientist – CAR T Cell Cancer Immunotherapies

Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States

Research Fellow – Adenocarcinoma

Dana-Farber Cancer Institute – Boston, Massachusetts, United States

Postdoctoral Fellowship – Ovarian Cancer

Harvard Medical School – Boston, Massachusetts, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter